who and why dumping, page-39

Because we are waiting for the follow up annoucements from this week onwards:


-Funding for Phase II (could be from ISIS, Other investors or Tempo)
-Phase II trial commences (3 months trial. I hope preparation work was done during the wait for Phase I result to fast track it)
-Prof Cohen result on anti cancer properties of ATL1103 (if positive, a new line of trials and licensing may be on)
-Afandin ATL1101 funding and JV deal (latest May 2012. This will be spinned off as a separate company as announced previously)
-Potential Licensing of ATL1103 for other application other that Acromegaly (As ANP wants to keep Acromegaly development, licensing for any other drugs that may be benifitted by ALT1103 could be considered )
-Potential partner for ATL1102 stem cell indication and ATL1102 stem cell patent approval.
-Offer from other Pharma that is 'too good to refused' for ATL1103


Any one this will trigger a re-rating.